Clinical Trial Update: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial of mirikizumab in moderately to severely active ulcerative colitis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic | Phase 3 | Status: COMPLETED | Results posted: 2025-09-30